重症虚血肢治療市場：治療タイプ別、エンドユーザー別-2025-2030年の世界予測

重症虚血肢治療市場は、2023年に41億1,000万米ドルと評価され、2024年には44億6,000万米ドルに達すると予測され、CAGR 8.84％で成長し、2030年には74億5,000万米ドルに達すると予測されています。

重症虚血肢（CLI）は、四肢への血流を著しく減少させる重度の動脈閉塞であり、治療しなければ切断の危険性があります。末梢動脈疾患や糖尿病などの慢性疾患の高い有病率によって必要とされるCLI治療は、患者の予後と生活の質を高めるために不可欠です。バイパス移植術や内膜剥離術のような外科的介入から、血管形成術を含む非外科的方法、そして新たな細胞ベースの治療法まで、その応用範囲は広いです。最終用途の範囲は病院、外来医療センター、血管専門クリニックに及び、効果的な治療に必要な集学的アプローチを反映しています。市場成長の原動力は、世界人口の高齢化、糖尿病罹患率の増加、医療技術の進歩です。しかし、発展途上地域における高額な治療費や不十分なヘルスケア・インフラなどの要因が課題となっています。規制上のハードルや臨床試験プロトコルの強化の必要性も、市場の進展を妨げています。主な潜在機会は低侵襲治療と個別化医療アプローチの開発にあり、生体吸収性スキャフォールドや幹細胞治療のようなイノベーションが有望視されています。バイオテクノロジー企業と研究機関の戦略的提携は、イノベーションを促進し、市場参入を強化することができます。十分なサービスを受けていない市場向けに経済的に実行可能なソリューションを開発することに重点を置くことが重要です。また、早期CLIの症状に対する患者やプライマリ・ケア提供者の認識不足も治療の遅れにつながっています。市場関係者は、理解を広め、早期診断を促進するための教育的取り組みに注力しなければならないです。遠隔医療やAIを活用した診断ツールなど、デジタルヘルス技術を活用することで、患者のモニタリングや治療効果を高める機会が豊富にあります。将来的には、ゲノミクスの進歩と、個別化された治療計画へのAIの統合が、大きな成長の道筋を示すことになります。課題はあるもの、CLI治療市場は、進行中の研究と患者中心主義に後押しされ、大きく前進する態勢を整えています。

市場力学：急速に進化する重症虚血肢治療市場の主要市場インサイトを公開

重症虚血肢治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 糖尿病と肥満の有病率の増加
  • 低侵襲手術と再生医療における技術革新
  • 早期診断と治療の選択肢に関する患者や臨床医の意識の高まり
• 市場抑制要因
  • 合併症のリスク
• 市場機会
  • 幹細胞治療と遺伝子治療の革新
  • ロボット手術とハイブリッド手術室の進歩
• 市場の課題
  • 高度な治療法に伴う高コスト

ポーターのファイブフォース：重症虚血肢治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：重症虚血肢治療市場における外部からの影響の把握

外部マクロ環境要因は、重症虚血肢治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析重症虚血肢治療市場における競合情勢の把握

重症虚血肢治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス重症虚血肢治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、重症虚血肢治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨重症虚血肢治療市場における成功への道筋を描く

重症虚血肢治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 糖尿病と肥満の増加
    • 低侵襲手術と再生医療におけるイノベーション
    • 早期診断と治療の選択肢に関する患者と医師の意識の向上
  • 抑制要因
    • 手術合併症のリスク
  • 機会
    • 幹細胞治療と遺伝子治療におけるイノベーション
    • ロボット手術とハイブリッド手術室の進歩
  • 課題
    • 高度な治療法に伴う高額な費用
• 市場セグメンテーション分析
  • 治療の種類：低侵襲手術としての血管形成術とステント留置術の採用
  • 最終用途：CLI患者の診断、治療、救急医療における病院の重要性
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 重症虚血肢治療市場治療の種類別

• 血管形成術とステント留置術
• 動脈内膜切除術
• 高圧酸素療法
• 薬物治療
• 外科的バイパス

第7章 重症虚血肢治療市場：最終用途別

• 在宅医療
• 病院
• 外来手術センター
• 血管専門クリニック
• 創傷ケアセンター

第8章 南北アメリカの重症虚血肢治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の重症虚血肢治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの重症虚血肢治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • アボットのエスプリBTKシステムによる重篤な四肢麻痺を伴う虚血の高度な治療
  • リムフローシステムは、切断の危機に瀕する重度の末梢動脈疾患患者に新たな希望をもたらす
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Ambulero Inc
• Amgen Inc.
• Antidote Therapeutics Inc
• Athersys Inc
• Boston Scientific Corporation
• Caladrius Biosciences Inc
• Cardiovascular Systems, Inc.
• Cesca Therapeutics Inc.
• Constant Therapeutics LLC
• Cynata Therapeutics Ltd
• Eli Lilly and Company
• Gurus BioPharm Inc
• Helixmith Co Ltd
• Hemostemix Inc
• ID Pharma Co Ltd
• ImmuneCyte Inc
• Ixaka Ltd
• LimFlow SA
• Lisata Therapeutics
• Medtronic plc
• Micro Medical Solutions
• Novartis AG
• Pluristem Therapeutics Inc.
• Rexgenero Ltd.
• Sanofi S.A.
• Stempeutics Research Pvt Ltd.
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. CRITICAL LIMB ISCHEMIA TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. CRITICAL LIMB ISCHEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CRITICAL LIMB ISCHEMIA TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY & STENTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDARTERECTOMY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HYPERBARIC OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL BYPASS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOME HEALTH CARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY OUTPATIENT SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALIZED VASCULAR CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY WOUND CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 26. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 27. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 28. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 29. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 31. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 35. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 36. AUSTRALIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 37. AUSTRALIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 38. CHINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 39. CHINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 40. INDIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 41. INDIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 42. INDONESIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 43. INDONESIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 44. JAPAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 45. JAPAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 46. MALAYSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 47. MALAYSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 48. PHILIPPINES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. PHILIPPINES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 50. SINGAPORE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 51. SINGAPORE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 52. SOUTH KOREA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 53. SOUTH KOREA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 54. TAIWAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 55. TAIWAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 56. THAILAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 57. THAILAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 58. VIETNAM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 59. VIETNAM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 61. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 62. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 63. DENMARK CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 64. DENMARK CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 65. EGYPT CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 66. EGYPT CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 67. FINLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 68. FINLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 69. FRANCE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 70. FRANCE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 71. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 72. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 73. ISRAEL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 74. ISRAEL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 75. ITALY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. ITALY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 77. NETHERLANDS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 78. NETHERLANDS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 79. NIGERIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. NIGERIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 81. NORWAY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 82. NORWAY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 83. POLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 84. POLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 85. QATAR CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 86. QATAR CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 87. RUSSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 88. RUSSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 89. SAUDI ARABIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SAUDI ARABIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 93. SPAIN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 94. SPAIN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 95. SWEDEN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. SWEDEN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 97. SWITZERLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 98. SWITZERLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 99. TURKEY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. TURKEY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 101. UNITED ARAB EMIRATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 102. UNITED ARAB EMIRATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 103. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 104. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 105. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 106. CRITICAL LIMB ISCHEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Critical Limb Ischemia Treatment Market was valued at USD 4.11 billion in 2023, expected to reach USD 4.46 billion in 2024, and is projected to grow at a CAGR of 8.84%, to USD 7.45 billion by 2030.

Critical Limb Ischemia (CLI) is a severe obstruction of the arteries which significantly reduces blood flow to the extremities and poses a risk of amputation if untreated. Necessitated by the high prevalence of peripheral arterial disease and associated chronic conditions like diabetes, CLI treatment is vital for enhancing patient outcomes and quality of life. Applications range from surgical interventions, such as bypass grafting and endarterectomy, to non-surgical methods including angioplasty, and emerging cell-based therapies. The end-use scope spans hospitals, ambulatory care centers, and specialized vascular clinics, reflecting the multidisciplinary approach required for effective treatment. Market growth is driven by an aging global population, increasing incidence of diabetes, and advancements in medical technologies. However, factors like high treatment costs and inadequate healthcare infrastructure in developing regions present challenges. Regulatory hurdles and the need for enhanced clinical trial protocols also impede market progress. Key potential opportunities lie in the development of minimally invasive treatments and personalized medicine approaches; innovations like bioresorbable scaffolds and stem cell therapies show promise. Strategic collaborations between biotech firms and research institutions can expedite innovation and enhance market entry. Emphasis on developing economically viable solutions for underserved markets is crucial. Limitations also stem from a lack of awareness among patients and primary care providers about early-stage CLI symptoms, which delays treatment. Market players must focus on educational initiatives to broaden understanding and foster early diagnosis. Opportunities abound in leveraging digital health technologies, including telemedicine and AI-driven diagnostic tools, which enhance patient monitoring and treatment efficacy. Looking forward, advancements in genomics and the integration of AI in personalized treatment plans represent substantial avenues for growth. Despite its challenges, the CLI treatment market is poised for significant advancements fueled by ongoing research and a patient-centric focus.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Critical Limb Ischemia Treatment Market

The Critical Limb Ischemia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of diabetes and obesity
  • Innovations in minimally invasive procedures and regenerative medicine
  • Increased patient and clinician awareness about early diagnosis and treatment options
• Market Restraints
  • Risk of procedural complications
• Market Opportunities
  • Innovations in stem cell therapy and gene therapy
  • Advances in robotic surgery and hybrid operating rooms
• Market Challenges
  • High costs associated with advanced treatment modalities

Porter's Five Forces: A Strategic Tool for Navigating the Critical Limb Ischemia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Critical Limb Ischemia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Critical Limb Ischemia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Critical Limb Ischemia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Critical Limb Ischemia Treatment Market

A detailed market share analysis in the Critical Limb Ischemia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Critical Limb Ischemia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Critical Limb Ischemia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Critical Limb Ischemia Treatment Market

A strategic analysis of the Critical Limb Ischemia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Critical Limb Ischemia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ambulero Inc, Amgen Inc., Antidote Therapeutics Inc, Athersys Inc, Boston Scientific Corporation, Caladrius Biosciences Inc, Cardiovascular Systems, Inc., Cesca Therapeutics Inc., Constant Therapeutics LLC, Cynata Therapeutics Ltd, Eli Lilly and Company, Gurus BioPharm Inc, Helixmith Co Ltd, Hemostemix Inc, ID Pharma Co Ltd, ImmuneCyte Inc, Ixaka Ltd, LimFlow SA, Lisata Therapeutics, Medtronic plc, Micro Medical Solutions, Novartis AG, Pluristem Therapeutics Inc., Rexgenero Ltd., Sanofi S.A., Stempeutics Research Pvt Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Critical Limb Ischemia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment Type, market is studied across Angioplasty & Stenting, Endarterectomy, Hyperbaric Oxygen Therapy, Medication, and Surgical Bypass.
• Based on End-Use, market is studied across Home Health Care, Hospitals, Outpatient Surgical Centers, Specialized Vascular Clinics, and Wound Care Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of diabetes and obesity
    • 5.1.1.2. Innovations in minimally invasive procedures and regenerative medicine
    • 5.1.1.3. Increased patient and clinician awareness about early diagnosis and treatment options
  • 5.1.2. Restraints
    • 5.1.2.1. Risk of procedural complications
  • 5.1.3. Opportunities
    • 5.1.3.1. Innovations in stem cell therapy and gene therapy
    • 5.1.3.2. Advances in robotic surgery and hybrid operating rooms
  • 5.1.4. Challenges
    • 5.1.4.1. High costs associated with advanced treatment modalities
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Adoption of angioplasty and stenting as minimally invasive procedures
  • 5.2.2. End-Use: Importance of hospitals in the diagnosis, treatment, and emergency care of CLI patients
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Critical Limb Ischemia Treatment Market, by Treatment Type

• 6.1. Introduction
• 6.2. Angioplasty & Stenting
• 6.3. Endarterectomy
• 6.4. Hyperbaric Oxygen Therapy
• 6.5. Medication
• 6.6. Surgical Bypass

7. Critical Limb Ischemia Treatment Market, by End-Use

• 7.1. Introduction
• 7.2. Home Health Care
• 7.3. Hospitals
• 7.4. Outpatient Surgical Centers
• 7.5. Specialized Vascular Clinics
• 7.6. Wound Care Centers

8. Americas Critical Limb Ischemia Treatment Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Critical Limb Ischemia Treatment Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Critical Limb Ischemia Treatment Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. Advanced Treatment for Critical Limb-Threatening Ischemia with Abbott's Esprit BTK System
  • 11.3.2. LimFlow System Offers New Hope for Severe Peripheral Artery Disease Patients Facing Amputation
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Ambulero Inc
• 3. Amgen Inc.
• 4. Antidote Therapeutics Inc
• 5. Athersys Inc
• 6. Boston Scientific Corporation
• 7. Caladrius Biosciences Inc
• 8. Cardiovascular Systems, Inc.
• 9. Cesca Therapeutics Inc.
• 10. Constant Therapeutics LLC
• 11. Cynata Therapeutics Ltd
• 12. Eli Lilly and Company
• 13. Gurus BioPharm Inc
• 14. Helixmith Co Ltd
• 15. Hemostemix Inc
• 16. ID Pharma Co Ltd
• 17. ImmuneCyte Inc
• 18. Ixaka Ltd
• 19. LimFlow SA
• 20. Lisata Therapeutics
• 21. Medtronic plc
• 22. Micro Medical Solutions
• 23. Novartis AG
• 24. Pluristem Therapeutics Inc.
• 25. Rexgenero Ltd.
• 26. Sanofi S.A.
• 27. Stempeutics Research Pvt Ltd.
• 28. Teva Pharmaceutical Industries Ltd.